Early data in mice and human tissue indicate that using drugs or gene therapy could allow for cardiac healing in ischemic HF.

For the investigator-initiated ATTENUATE trial, researchers used the 11 x 34” RADPAD Orange, which Medranda calls a ...

Poor performance on quality metrics carried greater risk of in-hospital mortality no matter where patients initially ...

For many of these conditions, women present later and sicker, and are less likely to be treated appropriately.

CV risk factors don’t just impact heart health, but also affect other organs, including the brain, say experts.

More potent DAPT strategies and oral anticoagulation were tied to worse outcomes and should be avoided, researchers say.

With no differences between single or dual antiplatelet therapy or anticoagulants at 6 months, an RCT is warranted for ...

More research is needed to see how this factor could inform risk tools and whether addressing it reduces future disease.

There are hints that the 10-year benefit seen in STICHES, the earlier trial, might be the result of inferior medical therapy.

Even modern cancer treatments appear risky for the heart, especially if the radiation dose to the LAD is high.

Overall, though, the meta-analysis identified a reduction in ischemia—but not in hard outcomes—with early treatment.

The DCB looks good in select cases, but given its high price tag, exactly when to use it is still up for discussion, say ...